(Reuters) -Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said.

Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based pharma isn’t throwing in the towel just yet. At the same time ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...

After the Federal Circuit’s denial last month of Regeneron’s motion for an injunction pending appeal, seeking to prevent Amgen from ...

2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

For Amgen, Citi analysts underscore the potential of its obesity and diabetes drug, MariTide, though the firm remains cautious due to competitive pressures in the GLP-1 market. They believe the ...

Oct 22 (Reuters) - Amgen (AMGN.O), opens new tab will launch its biosimilar version of Regeneron's (REGN.O), opens new tab blockbuster eye care drug Eylea following a U.S. appeals court ruling in ...